Docoh
Loading...
Sign up Log in

LLY Lilly(Eli) & Co

Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. It was founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today it remains true to that mission in all its work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

Company profile

Ticker
LLY
Exchange
NYSE
Website
www.lilly.com
CEO
David Ricks
Employees
Incorporated
Indiana
Location
Indiana
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Viatris • Warner Chilcott • Abbvie ...
Former names
LILLY ELI & CO, LILLY ELI & CO ET AL
SEC CIK
0000059478
Corporate docs
IRS number
350470950

LLY stock data

(
)

News

Pro users get this 30m faster
Another Big Earnings Week Ahead
3 Aug 21
After a monumental week of Big Tech earnings, we're in for more than a quarter of S&P 500 companies' reports, including those from Alibaba (NYSE: BABA), General Motors (NYSE: GM), and Kraft Heinz
Stocks That Hit 52-Week Highs On Tuesday
3 Aug 21
During Tuesday's morning trading, 101 companies set new 52-week highs.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
3 Aug 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2)
Eli Lilly: Q2 Earnings Insights
3 Aug 21
Lilly Stock Slips On Mixed Bag Q2 Earnings, Cuts FY21 Sales Outlook For COVID-19 Therapies
3 Aug 21

Press releases

Pro users get this 30m faster
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
3 Aug 21
INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced financial results for the second quarter of 2021. "We delivered strong performance this quarter, with volume-driven growth
Lilly and Incyte's baricitinib reduced deaths among patients with COVID-19 receiving invasive mechanical ventilation
3 Aug 21
INDIANAPOLIS, Aug. 3, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today results from an additional cohort of 101 adult patients from the COV-BARRIER trial. In this sub-study,
CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders
29 Jul 21
New Director Dr. Jennifer K. Simpson Added to CytRx Board of Directors
FDA broadens existing emergency use of Lilly and Incyte's baricitinib in patients hospitalized with COVID-19 requiring oxygen
29 Jul 21
Lilly and Kumquat Biosciences Announce Collaboration to Discover and Develop Novel Small Molecules that Stimulate Tumor-Specific Immune Responses
29 Jul 21

Calendar

3 Aug 21
4 Aug 21
31 Dec 21

Financial summary

Financial statements Chart LLY financial data
Quarter (USD)
 Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Recent insider trades

LLY insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
21 Jul 21 Lilly Endowment Common Stock Sell Dispose S No No 237 86,111 20.41M 108,762,100
20 Jul 21 Lilly Endowment Common Stock Sell Dispose S No No 237.055 15,610 3.7M 108,848,211
19 Jul 21 Kimberly H Johnson Common Stock Grant Aquire A No No 234.14 41 9.6K 235
19 Jul 21 Tai Jackson P Common Stock Grant Aquire A No No 234.14 8 1.87K 61,274
19 Jul 21 Alvarez Ralph Common Stock Grant Aquire A No No 234.14 47 11K 49,849
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q1 2021

LLY institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

70.1% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 1899 1848 +2.8%
Opened positions 176 243 -27.6%
Closed positions 125 132 -5.3%
Increased positions 653 640 +2.0%
Reduced positions 752 660 +13.9%
13F shares
 Current Prev Q Change
Total value 125.32B 132.62B -5.5%
Total shares 671.87M 785.58M -14.5%
Total puts 5.42M 4.46M +21.5%
Total calls 4.33M 4.41M -1.8%
Total put/call ratio 1.3 1.0 +23.6%
Largest owners
 Shares Value Change
Vanguard 69.29M $12.94B +0.9%
BLK Blackrock 59.07M $11.04B +0.4%
PNC PNC Financial Services 52.21M $9.75B -0.2%
Primecap Management 35.38M $6.61B -3.8%
STT State Street 32.51M $6.07B -2.9%
Wellington Management 31.79M $5.94B -4.1%
FMR 30.85M $5.76B +20.4%
TROW T. Rowe Price 26.16M $4.89B +116.3%
State Farm Mutual Automobile Insurance 18.62M $3.48B 0.0%
JPM JPMorgan Chase & Co. 17.33M $3.24B -19.4%
Largest transactions
 Shares Bought/sold Change
Lilly Endowment 0 -111.13M EXIT
TROW T. Rowe Price 26.16M +14.06M +116.3%
Capital World Investors 14.6M +11.75M +411.7%
Norges Bank 0 -8.67M EXIT
FMR 30.85M +5.22M +20.4%
JPM JPMorgan Chase & Co. 17.33M -4.18M -19.4%
Jennison Associates 5.44M +3.56M +189.5%
Capital International Investors 8.89M -2.48M -21.8%
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main 486.57K -2.09M -81.1%
Citadel Advisors 111.68K -2.01M -94.7%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Management Discussion
  • Item 2. Management’s Discussion and Analysis of Results of Operations and Financial Condition
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: admissibility, admitting, Alpha, Appellate, AstraZeneca, authorisation, bebtelovimab, Branchburg, broadened, Chancery, circulation, contrary, core, Delta, destocking, Division, dominant, Economy, EO, ESI, expiry, fact, Fee, Gamma, GGG, hearing, interlocutory, Kumquat, letter, lien, LP, Miami, MiNA, Mosaic, notified, pathway, premium, preserved, Protomer, refractory, restraining, resurgent, Rome, shipment, site, stimulate, strong, temporary, unchanged, User, variant, Vienna, Western, withdrawn
Removed: agreed, finally, growth, Notwithstanding, protracted, quickly, remove, resolved, sheet, transition, ultimate, valid
From filing 10-Q 2021 Q2

Financial reports

View all
10-Q
2021 Q2
Quarterly report
3 Aug 21
10-Q
2021 Q1
Quarterly report
30 Apr 21
10-K
2020 FY
Annual report
17 Feb 21
10-Q
2020 Q3
Quarterly report
28 Oct 20
10-Q
2020 Q2
Quarterly report
31 Jul 20
10-Q
2020 Q1
Quarterly report
1 May 20
10-K
2019 FY
Annual report
19 Feb 20
10-Q
2019 Q3
Quarterly report
25 Oct 19
10-Q
2019 Q2
Quarterly report
2 Aug 19
10-Q
2019 Q1
Quarterly report
2 May 19

Current reports

View all
8-K
Updates 2021 Financial Guidance
3 Aug 21
8-K
Other Events
27 May 21
8-K
Submission of Matters to a Vote of Security Holders
5 May 21
8-K
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
27 Apr 21
8-K
Departure of Directors or Certain Officers
17 Feb 21
8-K
Departure of Directors or Certain Officers
9 Feb 21
8-K
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
29 Jan 21
8-K
Departure of Directors or Certain Officers
14 Jan 21
8-K
Lilly Announces 2021 Financial Guidance, Updates 2020 Guidance
15 Dec 20
8-K
Lilly Reports Third-Quarter Financial Results, Updates Guidance
27 Oct 20

Registration and prospectus

View all
SC TO-T/A
Third party tender offer statement (amended)
22 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
20 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
14 Jan 21
SC TO-T/A
Third party tender offer statement (amended)
5 Jan 21
SC TO-T
Third party tender offer statement
22 Dec 20
SC TO-C
Information about tender offer
15 Dec 20
424B2
Prospectus for primary offering
21 Aug 20
FWP
Free writing prospectus
20 Aug 20
424B2
Prospectus for primary offering
20 Aug 20
424B5
Prospectus supplement for primary offering
27 Apr 20

Proxies

View all
DEFA14A
Additional proxy soliciting materials
20 Apr 21
PX14A6G
Letter to shareholders
29 Mar 21
PX14A6G
Letter to shareholders
29 Mar 21
PX14A6G
Letter to shareholders
24 Mar 21
DEFA14A
Additional proxy soliciting materials
19 Mar 21
DEF 14A
Definitive proxy
19 Mar 21
PRE 14A
Preliminary proxy
18 Feb 21
PX14A6G
Letter to shareholders
27 Apr 20
DEFA14A
Additional proxy soliciting materials
15 Apr 20
DEFA14A
Additional proxy soliciting materials
7 Apr 20

Other

View all
SD
Conflict minerals disclosure
5 May 21
CORRESP
Correspondence with SEC
4 Jan 21
SD
Conflict minerals disclosure
5 May 20
SD
Conflict minerals disclosure
9 May 19
SD
Conflict minerals disclosure
16 May 18
SD
Conflict minerals disclosure
29 May 17
NO ACT
No action letter
8 Mar 17
NO ACT
No action letter
22 Feb 17
NO ACT
No action letter
9 Feb 17
NO ACT
No action letter
12 Jan 17

Ownership

View all
4
Change in insider ownership
22 Jul 21
4
ELI LILLY & Co / Ralph Alvarez ownership change
21 Jul 21
4
ELI LILLY & Co / JACKSON P TAI ownership change
21 Jul 21
4
ELI LILLY & Co / KIMBERLY H JOHNSON ownership change
21 Jul 21
4
Change in insider ownership
21 Jul 21
4
Change in insider ownership
15 Jul 21
4
Change in insider ownership
13 Jul 21
4
Change in insider ownership
12 Jul 21
4
Change in insider ownership
7 Jul 21
4
Change in insider ownership
6 Jul 21

Patents

View all
GRANT
Design
Autoinjector
3 Aug 21
Inventors: Delroy George Dennisur, Hemant Thakorbhai Patel, Amin Sedighiamiri, Parker Eugene Trow, Hsuan Tsun Wang
GRANT
Utility
Anti-N3pGlu amyloid beta peptide antibodies and uses thereof
3 Aug 21
Antibodies to human N3pGlu Aβ, compositions comprising such N3pGlu Aβ antibodies, and methods of using such N3pGlu Aβ antibodies for the treatment of a disease characterized by deposition of Aβ including clinical or pre-clinical Alzheimer's disease, Down's syndrome, and clinical or pre-clinical cerebral amyloid angiopathy.
APP
Utility
7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE Compounds As Mutant IDH1 and IDH2 Inhibitors
29 Jul 21
Inventors: Renato Alejandro BAUER, Serge Louis BOULET, Timothy Paul BURKHOLDER, Raymond GILMOUR, Patric James HAHN, Zoran RANKOVIC
GRANT
Utility
Dose detection system module for medication delivery device
27 Jul 21
Dose detection systems for medication delivery devices are described.
APP
Utility
Incretin Analogs and Uses Thereof
22 Jul 21
Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors.

Transcripts

View all
2021 Q2
Earnings call transcript
3 Aug 21
2021 Q1
Earnings call transcript
27 Apr 21
2020 Q4
Earnings call transcript
29 Jan 21
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q3
Earnings call transcript
27 Oct 20
2020 Q2
Earnings call transcript
30 Jul 20
2020 Q1
Earnings call transcript
23 Apr 20
2019 Q4
Earnings call transcript
30 Jan 20
2019 Q3
Earnings call transcript
23 Oct 19
2019 Q2
Earnings call transcript
30 Jul 19

Reddit threads

View all